SI3518933T1 - Metode zdravljenja materničnih miom in endometrioze - Google Patents

Metode zdravljenja materničnih miom in endometrioze

Info

Publication number: SI3518933T1
Authority: SI; Slovenia
Prior art keywords: endometriosis; methods; uterine fibroids; treating uterine; treating
Prior art date: 2016-09-30

Application number

SI201731123T

Other languages

English (en)

Inventor

Brendan Mark Johnson

Lynn Seely

JR. Paul N. MUDD

Susan Wollowitz

Mark Hibberd

Masataka Tanimoto

Vijaykumar Reddy Rajasekhar

Mayukh Vasant Sukhatme

Original Assignee

Myovant Sciences Gmbh

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-30

Filing date

2017-09-29

Publication date

2022-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3518933(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-09-29 Application filed by Myovant Sciences Gmbh, Takeda Pharmaceutical Company Limited filed Critical Myovant Sciences Gmbh

2022-06-30 Publication of SI3518933T1 publication Critical patent/SI3518933T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Surgical Instruments (AREA)

SI201731123T 2016-09-30 2017-09-29 Metode zdravljenja materničnih miom in endometrioze SI3518933T1 (sl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201662402150P	2016-09-30	2016-09-30
US201662402034P	2016-09-30	2016-09-30
US201662402055P	2016-09-30	2016-09-30
US201762492839P	2017-05-01	2017-05-01
US201762528409P	2017-07-03	2017-07-03
EP17823018.1A EP3518933B1 (en)	2016-09-30	2017-09-29	Methods of treating uterine fibroids and endometriosis
PCT/EP2017/074907 WO2018060501A2 (en)	2016-09-30	2017-09-29	Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number	Publication Date
SI3518933T1 true SI3518933T1 (sl)	2022-06-30

Family

ID=60915460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201731123T SI3518933T1 (sl)	2016-09-30	2017-09-29	Metode zdravljenja materničnih miom in endometrioze

Country Status (22)

Country	Link
US (4)	US11033551B2 (sl)
EP (2)	EP4094766A1 (sl)
JP (1)	JP7043503B2 (sl)
CN (1)	CN110312512B (sl)
AU (2)	AU2017336363B2 (sl)
BR (1)	BR112019006227A2 (sl)
CA (1)	CA3038879A1 (sl)
CY (1)	CY1125254T1 (sl)
DK (1)	DK3518933T3 (sl)
ES (1)	ES2912929T3 (sl)
HR (1)	HRP20220708T1 (sl)
HU (1)	HUE059101T2 (sl)
IL (2)	IL300580A (sl)
LT (1)	LT3518933T (sl)
MD (1)	MD3518933T2 (sl)
MX (1)	MX2019003726A (sl)
NZ (1)	NZ752916A (sl)
PL (1)	PL3518933T3 (sl)
PT (1)	PT3518933T (sl)
RS (1)	RS63300B1 (sl)
SI (1)	SI3518933T1 (sl)
WO (1)	WO2018060501A2 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3038875A1 (en)	2016-09-30	2018-04-05	Myovant Sciences Gmbh	Treatment of prostate cancer
SI3518933T1 (sl)	2016-09-30	2022-06-30	Myovant Sciences Gmbh	Metode zdravljenja materničnih miom in endometrioze
JP7292566B2 (ja)	2017-06-05	2023-06-19	キッセイ薬品工業株式会社	子宮筋腫を治療し、月経失血を低下させるゴナドトロピン放出ホルモンアンタゴニスト投与計画
AU2018280742B2 (en)	2017-06-05	2023-12-21	Kissei Pharmaceutical Co., Ltd.	Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
JP2021531236A (ja) *	2018-04-19	2021-11-18	アッヴィ・インコーポレイテッド	重度の月経出血を治療する方法
CA3117092A1 (en) *	2018-10-29	2020-05-07	ObsEva S.A.	Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) *	2019-04-16	2020-01-20	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта"	Способ лечения наружного генитального эндометриоза
CN110194776B (zh) *	2019-06-27	2021-05-28	四川伊诺达博医药科技有限公司	一种瑞卢戈利的合成方法
CN114466665A (zh) *	2019-08-08	2022-05-10	奥布赛瓦股份公司	用于治疗雌激素依赖性病症的组合物和方法
EP4041738A1 (en) *	2019-10-10	2022-08-17	Myovant Sciences GmbH	Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN115279769A (zh) *	2019-10-10	2022-11-01	梦欧文科学有限责任公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
KR20230011266A (ko) *	2020-02-19	2023-01-20	아스피라 위민스 헬스 인크.	개선된 특이성을 갖는 자궁내막증 평가를 위한 조성물
CN113384581B (zh) *	2020-03-12	2023-11-14	成都倍特药业股份有限公司	一种包含促性腺激素释放激素拮抗剂的药物组合物
PE20230859A1 (es)	2020-05-29	2023-05-30	Myovant Sciences Gmbh	Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina
JP2023549196A (ja)	2020-11-11	2023-11-22	ミオバントサイエンシズゲーエムベーハー	レルゴリクスの投与方法
WO2023066941A1 (en)	2021-10-18	2023-04-27	Myovant Sciences Gmbh	Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2024015934A2 (en) *	2022-07-13	2024-01-18	Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods of diagnostic screening and early detection of adenomyosis
TW202428262A (zh) *	2022-11-09	2024-07-16	美商坦帕斯醫療公司	三唑酮化合物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US402055A (en)		1889-04-23		Water-motor
US402034A (en)		1889-04-23		Dumping-wagon
US402150A (en)		1889-04-30		Broadcast seed-sower
US492839A (en)		1893-03-07		Key for brake-shoes
US528409A (en)		1894-10-30		Denis ahern
FR2512732A1 (fr)	1981-09-14	1983-03-18	Raffinage Cie Francaise	Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en)	1991-04-12	1994-08-23	University Of Southern California	Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es)	1996-01-11	1997-06-27		Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es)	1997-01-15	1998-04-07		Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de)	1998-04-03	1999-10-14	Jenapharm Gmbh	Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) *	1998-08-07	2001-07-24	Heinrichs William Leroy	Prevention of endometriosis signs or symptons
US6297379B1 (en)	1999-03-24	2001-10-02	Takeda Chemical Industries, Ltd.	Thienopyrimidine compounds, their production and use
TWI225863B (en)	1999-03-24	2005-01-01	Takeda Chemical Industries Ltd	Thienopyrimidine compounds, their production and use
KR20030005205A (ko)	2000-02-29	2003-01-17	다케다 야쿠힌 고교 가부시키가이샤	티에노피리미딘 유도체의 제조 방법
WO2003064429A1 (fr)	2002-01-30	2003-08-07	Takeda Chemical Industries, Ltd.	Thienopyrimidines, procedes de fabrication et d'utilisation correspondants
NZ541772A (en)	2003-01-29	2009-10-30	Takeda Pharmaceutical	Thienopyrimidine compounds and use thereof
KR101139148B1 (ko)	2003-07-07	2012-04-26	뉴로크린 바이오사이언시즈 인코퍼레이티드	고나도트로핀-방출 호르몬 수용체 길항제로서의피리미딘-2,4-디온 유도체
MY151322A (en)	2004-04-30	2014-05-15	Bayer Ip Gmbh	Management of breakthrough bleeding in extended hormonal contraceptive regimens
ZA200801150B (en)	2005-07-22	2010-05-26	Takeda Pharmaceutical	Premature ovulation preventive agent
TWI386417B (zh)	2005-12-22	2013-02-21	Takeda Pharmaceutical	轉移抑素衍生物及其用途
PE20090044A1 (es)	2007-04-06	2009-01-23	Neurocrine Biosciences Inc	Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
WO2009062087A1 (en)	2007-11-07	2009-05-14	Neurocrine Biosciences, Inc.	Processes for the preparation of uracil derivatives
WO2010026993A1 (ja)	2008-09-03	2010-03-11	武田薬品工業株式会社	製剤における吸収性改善方法および吸収性が改善された製剤
US9427418B2 (en)	2009-02-23	2016-08-30	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
US9624161B2 (en)	2009-02-23	2017-04-18	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
JP2013528626A (ja)	2010-06-16	2013-07-11	アンドルシェルシュ・インコーポレイテッド	エストロゲン関連疾患を治療するまたは予防するための方法
JP2012077020A (ja)	2010-09-30	2012-04-19	Mochida Pharmaceut Co Ltd	ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
LT3415517T (lt)	2012-09-28	2022-06-10	Takeda Pharmaceutical Company Limited	Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma
WO2014143669A1 (en) *	2013-03-15	2014-09-18	AbbVie Inc .	Compositions for use in treating heavy menstrual bleeding and uterine fibroids
PL3263110T3 (pl)	2015-02-26	2023-11-06	Takeda Pharmaceutical Company Limited	Tabletka zawierająca pochodną metoksymocznika i cząstki mannitolu
WO2017040841A1 (en)	2015-09-01	2017-03-09	Abbvie Inc.	Methods of administering elagolix
SI3518933T1 (sl)	2016-09-30	2022-06-30	Myovant Sciences Gmbh	Metode zdravljenja materničnih miom in endometrioze
CA3038875A1 (en)	2016-09-30	2018-04-05	Myovant Sciences Gmbh	Treatment of prostate cancer
AU2018280742B2 (en)	2017-06-05	2023-12-21	Kissei Pharmaceutical Co., Ltd.	Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN115279769A (zh)	2019-10-10	2022-11-01	梦欧文科学有限责任公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (en)	2019-10-10	2022-08-17	Myovant Sciences GmbH	Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
PE20230859A1 (es)	2020-05-29	2023-05-30	Myovant Sciences Gmbh	Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina
JP2023549196A (ja)	2020-11-11	2023-11-22	ミオバントサイエンシズゲーエムベーハー	レルゴリクスの投与方法
WO2023066941A1 (en)	2021-10-18	2023-04-27	Myovant Sciences Gmbh	Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

2017
- 2017-09-29 SI SI201731123T patent/SI3518933T1/sl unknown
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 IL IL300580A patent/IL300580A/en unknown
- 2017-09-29 EP EP22162349.9A patent/EP4094766A1/en active Pending
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 RS RS20220565A patent/RS63300B1/sr unknown
- 2017-09-29 EP EP17823018.1A patent/EP3518933B1/en active Active
- 2017-09-29 PL PL17823018T patent/PL3518933T3/pl unknown
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 DK DK17823018.1T patent/DK3518933T3/da active
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 ES ES17823018T patent/ES2912929T3/es active Active
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T1/hr unknown
- 2017-09-29 BR BR112019006227A patent/BR112019006227A2/pt unknown
- 2017-09-29 MD MDE20190880T patent/MD3518933T2/ro unknown
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en active Application Filing
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582C1/en active Active
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending

Also Published As

Publication number	Publication date
HRP20220708T1 (hr)	2022-07-22
CA3038879A1 (en)	2018-04-05
CN110312512A (zh)	2019-10-08
IL300580A (en)	2023-04-01
EP3518933A2 (en)	2019-08-07
CN110312512B (zh)	2023-05-09
IL265700B1 (en)	2023-03-01
LT3518933T (lt)	2022-06-10
JP7043503B2 (ja)	2022-03-29
JP2019529575A (ja)	2019-10-17
AU2017336363A1 (en)	2019-05-16
WO2018060501A3 (en)	2018-05-11
US20220370462A1 (en)	2022-11-24
PT3518933T (pt)	2022-05-10
RS63300B1 (sr)	2022-07-29
WO2018060501A2 (en)	2018-04-05
BR112019006227A2 (pt)	2019-06-18
ES2912929T3 (es)	2022-05-30
CY1125254T1 (el)	2024-02-16
EP3518933B1 (en)	2022-03-16
AU2017336363B2 (en)	2022-08-04
NZ752916A (en)	2022-09-30
EP4094766A1 (en)	2022-11-30
MD3518933T2 (ro)	2022-07-31
IL265700B2 (en)	2023-07-01
AU2022241582B2 (en)	2024-06-13
AU2022241582A1 (en)	2022-10-27
AU2022241582C1 (en)	2024-11-28
US11957684B2 (en)	2024-04-16
IL265700A (en)	2019-05-30
PL3518933T3 (pl)	2022-06-20
US20210401841A1 (en)	2021-12-30
US11793812B2 (en)	2023-10-24
US11033551B2 (en)	2021-06-15
DK3518933T3 (da)	2022-05-30
US20240165118A1 (en)	2024-05-23
MX2019003726A (es)	2019-09-26
HUE059101T2 (hu)	2022-10-28
US20190262346A1 (en)	2019-08-29

Publication	Publication Date	Title
IL265700A (en)	2019-05-30	Methods for treating uterine fibroids and endometrial disease
SG11201803619VA (en)	2018-05-30	Three-dimensional memory apparatuses and methods of use
HK1257761A1 (zh)	2019-10-25	用於測量限制的配置的方法和裝置
GB2549215B (en)	2018-07-25	Security devices and methods of manufacture thereof
IL252726A0 (en)	2017-08-31	Uterine clamps to treat postpartum bleeding and to help restore the uterus
IL265359A (en)	2019-05-30	Modified Oligonucleotides and Methods of Use
GB2550168B (en)	2018-07-25	Security device and method of manufacture
IL259096A (en)	2018-06-28	Peptides and methods of treating endometriosis using the same
GB201620675D0 (en)	2017-01-18	Photociode device and method of manufacture
IL272570A (en)	2020-03-31	Methods and preparations for the detection and treatment of endometriosis
SG10201405193QA (en)	2015-12-30	Hair extension device and related methods of manufacture
GB201600263D0 (en)	2016-02-24	Fixation device and method of manufacture and use
HK1250360A1 (zh)	2018-12-14	袋和製作袋的方法
GB2566975B (en)	2020-03-25	Security Device And Method Of Manufacture Thereof
HUE060394T2 (hu)	2023-02-28	Készítmények és módszerek az endometriózis kezelésére
SG10201702547QA (en)	2017-11-29	Methods of vibro-treating and vibro-treating apparatus
IL246637A0 (en)	2016-08-31	Preparations and methods for the treatment of intracerebral hemorrhage
IL274190A (en)	2020-06-30	Methods for treating ischemic disease
GB2556880B (en)	2020-06-10	Security device components and methods of manufacture thereof
IL248381A0 (en)	2016-11-30	A combination of brexpiprazole and nalemapine and its use in the treatment of drug-related disorders
PL3328529T3 (pl)	2020-01-31	Urządzenie do mieszania masy formierskiej i sposób mieszania masy formierskiej
GB2527908B (en)	2021-06-09	Closure means and method of use thereof
EP3324959C0 (en)	2023-07-12	LICOFELON DERIVATIVES AND METHODS OF USE
GB201600264D0 (en)	2016-02-24	Fixation device location and method of manufacture and use
GB201501257D0 (en)	2015-03-11	Cover means and method of use thereof